Novel Reporter Phages to Detect Complex TB Drug Resistance and Persistence
用于检测复杂结核病耐药性和持久性的新型报告噬菌体
基本信息
- 批准号:9060871
- 负责人:
- 金额:$ 65.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-05-01 至 2019-04-30
- 项目状态:已结题
- 来源:
- 关键词:AIDS/HIV problemAcid Fast Bacillae Staining MethodAdmission activityAntibiotic TherapyAntibioticsBacillus (bacterium)BacteriophagesBiological AssayBiological MarkersCase Fatality RatesCellsCharacteristicsClinicalClinical DataCollaborationsCommunitiesComplexDiagnosisDiagnosticDrug resistanceDrug resistance in tuberculosisEnglandEpidemicExtreme drug resistant tuberculosisFundingGenesGeneticHIVHIV/TBHospital ReferralsHumanIncidenceInfectionInstitutesLaboratoriesMeasuresMedicineMetabolicMultidrug-Resistant TuberculosisMycobacteriophagesMycobacterium tuberculosisNewly DiagnosedPathway interactionsPatientsPharmaceutical PreparationsPlasmidsPopulationPredispositionPrevalencePreventionPublic HealthRecombinantsRegimenReporterResearchResearch InstituteResearch PersonnelResistanceRifampicin resistanceRoleSamplingScientistSouth AfricaSputumTestingTreatment FailureTreatment outcomeTuberculosisWorkbasechemotherapycollegeextensive drug resistanceimprovedin vivoin vivo Modelinnovationkillingsmolecular diagnosticsmycobacterialnovelpreventpromoterpublic health relevanceresearch facilityresearch studyresistant strainsuccesstranscriptomicstransmission processtreatment durationtuberculosis treatment
项目摘要
DESCRIPTION (provided by applicant): Nowhere has drug-resistant TB generated more alarm than in South Africa, where synergies between endemic TB and HIV have caused 'explosive' increases in TB incidence and case- fatality rates. The most resistant form of TB, extensively drug resistant tuberculosis (XDR-TB), is increasingly prevalent in South Africa. An important obstacle to improving survival for XDR-TB is the lack of a rapid, biomarker that serves to identify viable Mtb, allow drug susceptibility testing in clinical sputum samples and detect Mtb
persisters. Utilizing two novel recombinant reporter mycobacteriophages, we have developed assays with superior test characteristics that will allow us to characterize complex drug resistance and mycobacterial persistence in vivo to improve treatment outcomes for drug-resistant TB/HIV patients. This proposal is a result of an ongoing funded collaboration between researchers at Albert Einstein College of Medicine, the KwaZulu-Natal Research Institute for Research in Tuberculosis and HIV/AIDS (K-RITH), and the Sanger Institute. This is an innovative approach with the potential to make a substantial impact in our ability to comprehensively diagnose drug-resistant tuberculosis and characterize Mtb persister populations thereby improving treatment outcomes, reducing transmission and preventing amplification of drug resistance on treatment.
描述(由申请人提供):耐药结核病在南非引起的恐慌最为严重,当地结核病和艾滋病毒之间的协同作用导致结核病发病率和病死率“爆炸式”增加。耐药性最强的结核病——广泛耐药结核病 (XDR-TB) 在南非日益流行。提高广泛耐药结核病生存率的一个重要障碍是缺乏快速的生物标志物来识别活的结核分枝杆菌,允许在临床痰样本中进行药物敏感性测试并检测结核分枝杆菌
坚持者。利用两种新型重组报告分枝杆菌噬菌体,我们开发了具有卓越测试特性的检测方法,使我们能够表征复杂的耐药性和体内分枝杆菌的持久性,以改善耐药结核病/艾滋病毒患者的治疗结果。该提案是阿尔伯特·爱因斯坦医学院、夸祖鲁-纳塔尔省结核病和艾滋病毒/艾滋病研究所 (K-RITH) 以及桑格研究所的研究人员持续资助合作的结果。这是一种创新方法,有可能对我们全面诊断耐药结核病和表征结核分枝杆菌持续人群的能力产生重大影响,从而改善治疗结果、减少传播并防止治疗中耐药性的放大。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michelle H Larsen其他文献
Michelle H Larsen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michelle H Larsen', 18)}}的其他基金
Advanced Genotypic and Phenotypic monitoring of Drug Resistant TB to Improve TB Treatment Outcomes
先进的耐药结核病基因型和表型监测可改善结核病治疗结果
- 批准号:
10403937 - 财政年份:2015
- 资助金额:
$ 65.05万 - 项目类别:
Advanced Genotypic and Phenotypic monitoring of Drug Resistant TB to Improve TB Treatment Outcomes
先进的耐药结核病基因型和表型监测可改善结核病治疗结果
- 批准号:
10610941 - 财政年份:2015
- 资助金额:
$ 65.05万 - 项目类别:
EFFICACY AND SAFETY OF LIVE ATTENUATED MYCOBACTERIUM TUBERCULOSIS VACCINES
结核分枝杆菌减毒活疫苗的功效和安全性
- 批准号:
8358085 - 财政年份:2011
- 资助金额:
$ 65.05万 - 项目类别:
EFFICACY AND SAFETY OF LIVE ATTENUATED MYCOBACTERIUM TUBERCULOSIS VACCINES
结核分枝杆菌减毒活疫苗的功效和安全性
- 批准号:
8172985 - 财政年份:2010
- 资助金额:
$ 65.05万 - 项目类别:
EFFICACY AND SAFETY OF LIVE ATTENUATED MYCOBACTERIUM TUBERCULOSIS VACCINES
结核分枝杆菌减毒活疫苗的功效和安全性
- 批准号:
7716315 - 财政年份:2008
- 资助金额:
$ 65.05万 - 项目类别:
相似海外基金
Patient reported outcomes in patients with nontuberculous mycobacterial pulmonary disease
非结核分枝杆菌肺病患者报告的结果
- 批准号:
10720789 - 财政年份:2023
- 资助金额:
$ 65.05万 - 项目类别:
The human lung and lung-draining lymph node response to Mycobacterium tuberculosis
人肺和肺引流淋巴结对结核分枝杆菌的反应
- 批准号:
10666017 - 财政年份:2023
- 资助金额:
$ 65.05万 - 项目类别:
Determining the performance and accuracy of SILVAMP TB LAM and cost-effectiveness of diagnostic testing for TB meningitis.
确定 SILVAMP TB LAM 的性能和准确性以及结核性脑膜炎诊断测试的成本效益。
- 批准号:
10650828 - 财政年份:2022
- 资助金额:
$ 65.05万 - 项目类别:
Genetic engineering of Mycobacterium leprae to Glow and Grow
麻风分枝杆菌发光和生长的基因工程
- 批准号:
10625474 - 财政年份:2022
- 资助金额:
$ 65.05万 - 项目类别:
Determining the performance and accuracy of SILVAMP TB LAM and cost-effectiveness of diagnostic testing for TB meningitis.
确定 SILVAMP TB LAM 的性能和准确性以及结核性脑膜炎诊断测试的成本效益。
- 批准号:
10548027 - 财政年份:2022
- 资助金额:
$ 65.05万 - 项目类别: